Sarepta Therapeutics Inc. (NASDAQ:SRPT) traded down 3% during mid-day trading on Thursday . The company traded as low as $25.36 and last traded at $25.41, with a volume of 1,300,851 shares traded. The stock had previously closed at $26.19.

A number of equities research analysts recently issued reports on the stock. Leerink Swann cut shares of Sarepta Therapeutics from a “market perform” rating to an “underperform” rating and dropped their target price for the stock from $13.00 to $5.00 in a research report on Monday, May 2nd. Oppenheimer Holdings Inc. reiterated a “buy” rating and set a $60.00 target price on shares of Sarepta Therapeutics in a research report on Sunday, July 17th. Robert W. Baird reiterated a “buy” rating on shares of Sarepta Therapeutics in a research report on Sunday, May 8th. Vetr cut shares of Sarepta Therapeutics from a “strong-buy” rating to a “hold” rating and set a $17.87 target price for the company. in a research report on Tuesday, May 3rd. Finally, Piper Jaffray Cos. reiterated a “sell” rating and set a $6.00 target price on shares of Sarepta Therapeutics in a research report on Saturday, June 4th. Five investment analysts have rated the stock with a sell rating, eight have given a hold rating and seven have given a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $24.29.

The company has a 50 day moving average of $24.42 and a 200 day moving average of $19.26. The company’s market cap is $1.28 billion.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its earnings results on Tuesday, July 19th. The company reported ($1.35) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.19) by $0.16. During the same period in the previous year, the business earned ($0.87) earnings per share. Analysts anticipate that Sarepta Therapeutics Inc. will post ($5.16) earnings per share for the current fiscal year.

An institutional investor recently raised its position in Sarepta Therapeutics stock. Jennison Associates LLC raised its position in shares of Sarepta Therapeutics Inc. (NASDAQ:SRPT) by 463.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 838,629 shares of the company’s stock after buying an additional 689,831 shares during the period. Jennison Associates LLC owned 1.85% of Sarepta Therapeutics worth $32,354,000 as of its most recent filing with the SEC.

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.